TOLREMO therapeutics AG, a privately held research-stage biotechnology company, announced the completion of a financing round with private investors in the amount of CHF 2.4 m. The proceeds will be used to advance the company’s discovery and development of breakthrough medicines to target drug resistance in cancer therapy.
VISCHER advised TOLREMO in this financing round. The VISCHER team includes Dr. Matthias Staehelin (Partner) and Luzius Zumstein (Associate), both Corporate.